• Kailera Therapeutics completed enrollment in its global Phase 3 KaiNETIC program testing once-weekly obesity drug candidate ribupatide injection.
• No results have been presented; topline data from all three trials are expected in mid-2028.
• The studies aim to show ribupatide can drive meaningful weight loss, including in severe obesity, with one trial benchmarking against semaglutide.
• The program enrolled about 4,900 adults across more than 200 sites in 11 countries, positioning the drug for a pivotal readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836566) on September 30, 2026, and is solely responsible for the information contained therein.